PatientsLikeMe ™

ALS
Join Now (It's free!)

Already a member? Log in

Share your real-world treatment experience
with patients just like you.
Select a community
ALS including PLS and PMA
Find out more about the PatientsLikeMe
ALS Community

See More Treatments

See all treatments in the PatientsLikeMe system shared by patients just like you.


Brand Names: Akamin, Minoclin

What is Minocycline? Minocycline is a second-generation, long-acting tetracycline. It is indicated in the treatment of a variety of bacterial infections, including brain and meningeal infections; it is ten times better able to enter the brain than other tetracycline antibiotics. A European trial in ALS starts in 2007. Read more...Click to read more below

See more information, including instructions, precautions, side effects, and interactions.


Reasons Taken

76 patients in the community are taking or have taken Minocycline.

Reason # Patients Percentage of patients
Slow my ALS progress 54 71%
Other 15 19%
disease-related symptoms 2 2%
General health 1 1%
Fatigue 1 1%

Dosages

Based on the patients currently taking Minocycline.

  0 mg Daily 50 mg As needed 20 mg Daily 50 mg Daily 100 mg Daily 200 mg Daily 400 mg Daily
  8 Number of Patients: 8 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 9 Number of Patients: 9 11 Number of Patients: 11 1 Number of Patients: 1  

Duration

How long current patients have been taking Minocycline or how long patients were taking Minocycline before stopping.

Currently taking Minocycline

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0
5

Stopped taking Minocycline

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
2
6
3
16
6
8
Why Patients Stopped Taking Minocycline (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 19 43% Did not seem to work: 43%
Doctor's advice 15 34% Doctor's advice: 34%
Side effects too severe 8 18% Side effects too severe: 18%
Other 8 18% Other: 18%
Personal research 5 11% Personal research: 11%
Course of treatment ended 4 9% Course of treatment ended: 9%
Expense 1 2% Expense: 2%
Not indicated 1 2% Not indicated: 2%


Back to top